Trials / Recruiting
RecruitingNCT05659524
Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery
Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery - The NOSE Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Lori Wood · Academic / Other
- Sex
- All
- Age
- 19 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-blinded, multicenter study evaluating the benefit of sinonasal irrigations following endoscopic pituitary surgery. The goal of this study is to create practice changing guidelines with objective data highlighting the importance of irrigations on postoperative outcomes for pituitary surgery.
Detailed description
This prospective study, coupled with the results of the recent POET study evaluating the role of antibiotics in postoperative outcomes for pituitary surgery, will guide physicians in the optimal management of patients following endoscopic pituitary surgery. The investigator group has an established record of completing multicenter studies (e.g., POET, TRANSPHER) that have influenced clinical practice guidelines, raised the profile of Barrow in the pituitary and skull base community, and resulted in numerous peer-reviewed publications and awards.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Nasal saline irrigation | The following nasal care recommendations have been approved by the study protocol committee for patients randomized to the treatment arm with saline irrigations: * Postoperative days 1 through 3: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. * Postoperative day 3 to week 12: patients will begin twice daily sinus irrigation rinse (e.g., NeilMed Sinus Rinse). They will perform 240 mL sinus rinses BID. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative. |
Timeline
- Start date
- 2020-12-18
- Primary completion
- 2028-12-31
- Completion
- 2029-12-31
- First posted
- 2022-12-21
- Last updated
- 2024-04-19
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05659524. Inclusion in this directory is not an endorsement.